Subscribe
shutterstock_2169738405_t_schneider
T. Schneider / Shutterstock.com
5 July 2022Big PharmaMuireann Bolger

Irish pharma company prevails in US pay-for-delay case

The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.
Americas
Generic maker pays $145m to settle antitrust suit
21 July 2022   California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.
Americas
Generic maker pays $145m to settle antitrust suit
21 July 2022   California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.

More on this story

Americas
FTC hits Amneal, Impax and Endo with antitrust suit
28 January 2021   The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.
Americas
Generic maker pays $145m to settle antitrust suit
21 July 2022   California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?